The Burden of Childhood Atopic Dermatitis in the Primary Care Setting: A Report from the Meta-LARC Consortium

Jinan Al-naqeeb, MD, MPH, Sankirtana Danner, MA, CCRP; Lyle J. Fagnan, MD, Katrina Ramsey, MPH, LeAnn Michaels, Julie Mitchell, Kelsey Branca, MPH, Cynthia Morris, PhD, MPH, Donald E. Nease, Jr., MD, Linda Zittleman, MSPH, Barcey Levy, MD, PhD, Jeanette Daly, RN, PhD, David Habn, MD, MS, Rowena J. Dolor, MD, MHS, Hywel C. Williams, DSc, FMedSci, Joanne R. Chalmers, PhD, BSc, Jon Hanifin, MD, Susan Toftie, RN, FNP, Katharine E. Zuckerman, MD, MPH, Karen Hansis, Mollie Gundersen, Julie Block, Francie Karr, Sandra Dunbrasky, MD, Kathy Siebe, CPNP, Kristen Dillon, MD, Ricardo Cibotti, PhD, Jodi Lapidus, PhD, and Eric L. Simpson, MD, MCR

Background: Little is known about the burden of atopic dermatitis (AD) encountered in US primary care practices and the frequency and type of skin care practices routinely used in children.

Objective: To estimate the prevalence of AD in children 0 to 5 years attending primary care practices in the United States and to describe routine skin care practices used in this population.

Design: A cross-sectional survey study of a convenience sample of children under the age of 5 attending primary care practices for any reason.

Setting: Ten primary care practices in 5 US states.

Results: Among 652 children attending primary care practices, the estimated prevalence of ever having AD was 24% (95% CI, 21–28) ranging from 15% among those under the age of 1 to 38% among those aged 4 to 5 years. The prevalence of comorbid asthma was higher among AD participants compared to those with no AD, namely, 12% and 4%, respectively (P < .001). Moisturizers with high water: oil ratios were most commonly used (ie, lotions) in the non-AD population, whereas moisturizers with low water:oil content (ie, ointments) were most common when AD was present.

Conclusions: Our study found a large burden of AD in the primary care practice setting in the US. The majority of households reported skin care practices that may be detrimental to the skin barrier, such as frequent bathing and the routine use of moisturizers with high water: oil ratios. Clinical trials are needed to identify which skin care practices are optimal for reducing the significant burden of AD in the community. (J Am Board Fam Med 2019;32:191–200.)

Keywords: Atopic Dermatitis, Prevalence, Primary Health Care, Skin Care
studies find similar high rates of disease prevalence and similar geographic variability in prevalence.\(^8,9\) Most of our understanding of AD prevalence in the United States stems from a limited number of national population-based surveys, which are now over 10 years old.\(^2,8,9\) Although they provide a reasonable estimate of population prevalence, population-based studies do not always accurately reflect the burden of a disease encountered in community health care settings—an important consideration for resource allocation by decision makers.\(^10,11\) A better understanding of the burden of AD and the associated allergic comorbidities encountered in primary care practices helps to plan disease prevention strategies appropriate to this setting. Prevention strategies that prevent AD development may also reduce allergic comorbidities that often follow AD development, such as allergic asthma.

Epidemiologic studies identify several risk factors for AD development, including climatic factors,\(^12\) cat ownership,\(^13\) proximity to traffic,\(^14\) early allergen sensitization, family history of atopic diseases, and an FLG gene mutation (a gene important for proper skin barrier function).\(^15\) In a large unselected cohort from the United Kingdom, skin barrier dysfunction as measured by transepidermal water loss at 2 days and 2 months of age was the strongest risk factor for AD development at 12 months of age, more so than an FLG mutation or family history of atopy.\(^15\)

Because of the role early skin barrier dysfunction may play in AD development, our group and others have been interested in how skin care practices and moisturizer use may modify AD disease risk. Currently, there are no data to support the need for routine emollient use in healthy newborns.\(^16\) However, 3 pilot trials suggest daily moisturizer therapy in high-risk populations may reduce the risk of developing AD by as much as 50%.\(^17–19\) The optimal type of moisturizer that protects against AD in not clear, although moisturizers with higher oil content are thought to enhance skin barrier function more so than lower oil content moisturizers.\(^20\) Because plain water and fragrances can be an irritant to skin, fragranced moisturizers with high water content may, in theory, be detrimental to skin barrier function. Some authors postulate that the increased use of fragranced lotions early in life may explain the rising epidemic of AD, although no studies have shown this association in a rigorous manner.\(^21\)

To develop and study novel skin care interventions as a prevention strategy for AD, data are needed regarding the routine skin practices currently used by US families. In preparation for a large community-based trial evaluating moisturizers for the prevention of AD, we sought to determine the prevalence of AD in children attending primary care settings by using a convenience sample of children under the age of 5 and aimed to describe current skin care practices used by parents on their children both with and without AD.

### Methods

**Study Design, Population, and Setting**

This study, named the Community-Based Assessment of Skin Care, Allergies and Eczema (CASCADE) study, was a cross sectional survey study conducted in 5 US states. CASCADE was a planning study to determine the feasibility of conducting a large, 5-year, community-based pragmatic randomized controlled clinical trial to test the hypothesis that certain skin care practices can prevent or delay AD and allergic comorbidities. Study participants were dyads of parents or guardians and children 0 to 5 years old attending 1 of 10 community-based pediatric (n = 6) and family medicine (n = 4) clinics located in Oregon, Wis-
consin, Colorado, North Carolina, and Iowa. These clinics were all members of a practice-based research network (PBRN) within their respective state and were a mix of rural and suburban practices. All participating PBRNs collaborate via the Meta-network Learning and Research Center (Meta-LARC) consortium, an administrative structure funded by the Agency for Health care Research and Quality encompassing almost 1,000 primary care practices and 7,000 clinicians (https://www.ohsu.edu/xd/outreach/oregon-rural-practice-based-research-network/meta-larc/index.cfm, accessed April, 2018). PBRNs serve as essential partners in translating academic research advances into real-world health improvements in the general ambulatory care population.22 The study was approved by the institutional review board (IRB#11116) of Oregon Health and Science University and recruited participants from April 2015 through January 2016.

Inclusion required being a parent or legal guardian, aged ≥18 years, of a child between the ages of 0 and 5 years who was a current patient at the participating clinic; respondents also needed to be able to read and write in either English or Spanish. Potential respondents were excluded if unable to complete the questionnaire due to mental or cognitive capacity, if they or another of the child’s parents had already completed the questionnaire (ascertained by self-report), or if the child had been born preterm at less than 25 weeks of pregnancy.

**Recruitment**

The Iowa PBRN recruited participants by mail only, whereas all other PRBNs used a combination of the following methods to capture as wide a sample as possible: in clinic while waiting for their appointments, mailed surveys, and electronic surveys via Research Electronic Data Capture (REDCap) hosted by Oregon Health and Science University. This flexibility in recruitment methods allowed for a minimal impact on clinic workflow that is critical to performing research in this setting. Clinic staff were instructed to broadly distribute the surveys to all eligible patients attending the clinic during the enrollment period, without selecting for any demographic or medical history to minimize selection bias. Due to the nature of the survey distribution in a busy practice setting, refusals were not recorded; thus, we are unable to report a participation rate.

**Instrument**

The questionnaire was completed by the child’s caregiver and included questions about AD history, symptoms, age of onset, presence of other atopic disorders, medications use, and skin care and bathing practices (Supplemental Figure 1.) The questionnaire was adapted from previous childhood AD surveys that have been used and validated in a community setting to measure the prevalence of AD.2,9,23

**AD and Severity Assessment**

A history of AD was determined by a positive response to the question “Have you ever been told by a health care provider that your child has eczema or atopic dermatitis?” A similar question has been shown to have adequate sensitivity and specificity to estimate the prevalence of AD in the United States.24–26 We assessed the effect of AD on the child’s sleep by asking how many nights in the past week the child’s sleep had been disturbed because of a red rash or eczema. AD severity was assessed by asking respondents to rate the rash or eczema as mild, moderate, or severe. This question has been used previously in epidemiologic studies to assess severity and found to be a good indicator of childhood AD burden.2,9,27

**Comorbidities and Family History**

A history of asthma and wheezing were measured using the questions “Has your child ever been diagnosed with asthma by a health care provider?” and “Has your child ever had wheezing?” Food allergies were measured by asking “Has your child ever been diagnosed with a food allergy by a health care provider?” Family history of any atopic condition was assessed by asking the question “Has at least 1 of your child’s parents or older brothers or sisters (related by blood) ever had any of the following conditions: eczema, asthma, or hay fever/spring-time allergies?” Parental history of asthma was considered positive if at least 1 of the parents had asthma. The questions were adapted from previously validated questions used in epidemiologic studies which measured comorbidities.28,29

**Skin Care and Bathing**

Moisturizer use was assessed by answering the question “do you use a moisturizer/lotion/oil on your child’s skin?” An affirmative response to the above question was followed by secondary ques-
tions about the type of moisturizer and the application site—all over the body or just on dry areas. Moisturizer type was assessed by asking the following question: “Which moisturizer(s) did you use on your child?” The answer choices included the most commonly used commercial moisturizers brands: CeraVe cream, Cetaphil cream, Vaseline/petroleum jelly, Sunflower seed oil, Aveeno, Aquaphor, Vanicream, and Johnson’s baby lotion. If the moisturizer that had been used was not listed in the answer choices that were given, the parents were instructed to check “other” and write what they were using. For a better understanding of current trends in moisturizer use, more than 1 answer was acceptable for this question. We stratified moisturizers based on their content: lotion, cream, ointment, or liquid oil. If the parents did not specify the type (ie, lotion, ointment, cream, or liquid oil), and the brand product could represent more than 1 type of moisturizer, the answer was excluded from analysis.

Moisturizer frequency and bathing or shower frequency was measured using the following questions: “Over the past 3 months, on average how many days per week was a moisturizer/ lotion/oil applied to your child’s skin” and “Over the past 3 months, on average how many days per week did your child receive either a bath or shower?” Moisturizer frequency was asked only in those participants who were using moisturizers, whereas bathing frequency was asked of the whole sample. We categorized frequency of moisturizer use and bathing into 2 categories: <4 and 4 days or more per week. Because the biological effect of most moisturizers lasts more than 24 hours, we considered 4 days a week or more to be frequent use.

Sample Size and Statistical Analysis
A sample size of approximately 250 was estimated to provide a reasonably precise sample of disease prevalence from age 0 to 5 years with a 95% CI within 5 percentage points. Our actual sample was significantly larger to obtain an adequate sample from all age groups and study sites. We excluded 9 respondents who failed to provide the child’s age (n = 5) and history of provider diagnosis of AD (n = 3), or both (n = 1); our final dataset included 652 children.

We calculated simple descriptive statistics overall and for AD and non-AD groups and tested differences with $\chi^2$ tests. To estimate age-specific characteristics of AD, we used predictive margins from a logistic regression model with clustered standard errors to account for correlation between respondents from the same clinic. Similarly, estimates of comorbid conditions and skin care practices resulted from logistic or log-binomial (relative risk) models with clustered standard errors and including age, in months, as a covariate to adjust for this effect. All analyses were performed using Stata SE for windows version 14 (Stata Corp, College Station, Texas).

Results
A total of 652 caregivers with children aged between 0 to 5 years participated in the study with 24% (95% CI, 21–28) overall parent-reported prevalence of AD. The mean ± standard deviation of age of participants was 22.5 ± 19.4 months, and the mean age at which AD first appeared was 9 ± 10.4 months. Those with AD were far more likely to experience dry skin than those in the non-AD group (63% vs 17%, $P < .001$). There were no significant differences between those with AD compared with the non-AD group in regard to sex, parent language, race/ethnicity, or geographic distribution. Participants’ characteristics are summarized in Table 1.

AD Prevalence and severity
As expected, AD prevalence steadily increased with age, ranging from 14.5% among children less than 1 year old to 38% among children 4 to 5 years old ($P < .001$). Overall, 58% of children with AD had mild symptoms, 39% had moderate, and only 3% (4 children) had severe disease. Among the same children with AD, 21% had reported AD-related sleep disturbance in the previous week. Although we did not detect trends in severity or AD-related sleep disturbance by age, prescriptions for eczema medications were common overall (75% of children with AD) and increased with age. A total of 67% and 69% of children less than 1 year of age and 1 to 2 year olds, respectively, were prescribed medication compared to higher percents, 75% and 86%, for older age groups (2 to 3 years, and 4 to 5 years, respectively; $P = .019$); see Table 2.

Comorbidities and Family History
Children with AD in this study had a higher reported prevalence of certain comorbidities with
known or suspected links to AD. Age adjusted prevalence of asthma was about 3 times as high in the AD group compared to the non-AD group (prevalence ratio [PR], 3.0; \(P < .001\)). History of wheezing, including wheezing without a cold, were higher among the AD population compared to the non-AD group (PR, 1.4 and 1.8; \(P < .05\)). Food allergies were 3.7 times more common among those with AD (\(P = .005\)). Family history of any atopic condition—a known risk factor for AD—was also significantly higher in the AD group (PR, 1.3; \(P < .001\)). (Table 3)

**Skin Care and Bathing**

Use of moisturizer (at any frequency) was common in the whole sample; however, it was found to be significantly higher among the AD group (90%) compared to the non-AD group (74%, \(P < .001\)). For children without AD, parents most commonly used lotions (64%) on their children, whereas parents of children with established AD most commonly used oil-rich moisturizers, such as cream or ointment (65%) possibly in response to guideline-driven recommendations for AD treatment by their health practitioners (Table 4). The mean number of days used per week for the overall sample was 4.3 and the mean number of daily bath/showers per week was 4.6. Among those who used moisturizer, the majority (65%) applied it 4 or more days per week and there was no significant difference in moisturizer frequency application when stratified by age (Table 5). Those with AD applied moisturizers more days per week than those in the non-AD group (4 or more days a week 75% vs 60%, \(P = .001\)). Overall, 41% of the children received a bath/shower less than 4 days/week, whereas 59% received a bath/shower 4 or more days per week. There was no significant difference in bathing frequency between those with AD compared to those without AD. When bathing frequency was examined

**Table 1. Population Characteristics by Atopic Dermatitis Status**

| Characteristic                        | Overall | AD     | No AD  | \(P\) value* |
|---------------------------------------|---------|--------|--------|--------------|
| N                                     | 652 (100)| 159 (100) | 493 (100) | <.001        |
| Child age (years)                     |         |        |        |              |
| <1                                    | 240 (37) | 35 (22) | 205 (42) |              |
| 1                                     | 165 (25) | 39 (25) | 126 (26) |              |
| 2                                     | 75 (12)  | 21 (13) | 54 (11)  |              |
| 3                                     | 55 (8)   | 19 (12) | 36 (7)   |              |
| 4                                     | 65 (10)  | 26 (16) | 39 (8)   |              |
| 5†                                    | 52 (8)   | 19 (12) | 33 (7)   |              |
| Child sex: Female                     | 321 (50) | 73 (46) | 248 (51) | .35          |
| Caregiver responded in Spanish        | 32 (5)   | 8 (5)  | 24 (5)   | .93          |
| Race/ethnicity                        |         |        |        | .53          |
| Hispanic, any race                    | 140 (21) | 30 (19) | 110 (22) |              |
| White non-Hispanic                    | 367 (56) | 91 (57) | 276 (56) |              |
| Black non-Hispanic                    | 75 (12)  | 24 (15) | 51 (10)  |              |
| Asian non-Hispanic                    | 11 (2)   | 2 (1)  | 9 (2)    |              |
| More than one race                    | 34 (5)   | 6 (4)  | 28 (6)   |              |
| Prefer not to say                     | 25 (4)   | 6 (4)  | 19 (4)   |              |
| Generally dry skin                    | 181 (28) | 99 (63) | 82 (17)  | <.001        |
| State                                 |         |        |        | 0.25         |
| Oregon                                | 212 (33) | 46 (29) | 166 (34) |              |
| Wisconsin                             | 78 (12)  | 21 (13) | 57 (12)  |              |
| Iowa                                  | 93 (14)  | 29 (18) | 64 (13)  |              |
| Colorado                              | 56 (9)   | 17 (11) | 39 (8)   |              |
| North Carolina                        | 213 (33) | 46 (29) | 167 (34) |              |

AD, atopic dermatitis; N, total no. of children.

*p value from \(\chi^2\) tests.

†Includes children 72 months (6 years, 0 months) of age.
by age, those who were under the age of 1 received
less baths/showers per week compared to the older
participants regardless of AD status (P = .001). Sum-
maries of skin care practices seem in Tables 4 and 5.

Discussion
We estimated the prevalence of AD among chil-
dren age 0 to 5 attending community-based pri-
mary care practices to be approximately 24%, with
a mean age of AD onset in the first year of life.
Parents reported that AD severity was mild in more
than half of participating children, and 20% of
those with AD had their sleep disturbed at least
once a week as a result of their AD. As anticipated,
a higher prevalence of AD-associated comorbidities
and a family history of atopic conditions were
found among those with AD. The majority of par-
ents were using some kind of moisturizer on their
child’s skin on a regular basis; children with AD
were more likely to receive creamy and oily mois-
turizers, whereas children without AD were receiv-
ing lotions primarily. This large community-based
study is the first study to describe the pediatric AD
burden within community-based primary care
practices and provides important insight into skin
care practices that may be modifiable in future
disease prevention studies.

A higher prevalence of AD (24%) was found in
children under the age of 5 in our study compared
to US population-based studies using data from the
National Survey of Children Health. Shaw et al.8
found prevalence rates ranging between 13.12%
and 14.73% among those under the age of 4. Sim-
ilar to our findings, previous studies of chronic

| Age Category | N  | % Prevalence of AD (95% CI) | Moderate/severe AD (95% CI) | Sleep disturbed in past week (95% CI) | Medication prescribed (95% CI) |
|--------------|----|-----------------------------|-----------------------------|--------------------------------------|---------------------------------|
| Overall      | 652| 24 (21–28)                  | 42 (36–47)                  | 21 (15–27)                           | 75 (68–82)                      |
| Child age <1 year | 240| 15 (12–17)                  | 48 (37–60)                  | 24 (11–37)                           | 67 (54–79)                      |
| 1 year       | 165| 24 (19–29)                  | 29 (13–44)                  | 15 (5–24)                            | 69 (56–82)                      |
| 2 to 3 Years | 130| 31 (22–40)                  | 41 (28–53)                  | 22 (6–39)                            | 75 (60–90)                      |
| 4 to 5 Years | 117| 38 (29–48)                  | 49 (31–66)                  | 22 (14–31)                           | 86 (76–97)                      |

Table 2. Atopic Dermatitis Prevalence and Severity and Medication Prescribed, by Age*

| Comorbidity                          | Overall (n = 652) | AD (n = 159) | No AD (n = 493) | Age-Adjusted Prevalence Ratio | PR* 95% CI | 95% CI | P value |
|--------------------------------------|-------------------|--------------|-----------------|------------------------------|------------|-------|--------|
| Asthma                               | 7 (5–8)           | 12 (9–16)    | 4 (3–6)         | 3.0 (1.8–4.9)                | <.001      |       |        |
| Wheezing without cold                | 6 (4–9)           | 9 (6–13)     | 5 (3–8)         | 1.8 (1.1–2.7)                | .011       |       |        |
| Wheezing (ever)                      | 21 (18–23)        | 26 (19–33)   | 19 (16–22)      | 1.4 (1.02–1.9)               | .038       |       |        |
| Food allergy                         | 4 (3–5)           | 8 (4–12)     | 2 (1–3)         | 3.7 (1.5–9.2)                | .005       |       |        |
| Family history of atopic condition   | 69 (63–75)        | 82 (74–90)   | 65 (59–71)      | 1.3 (1.2–1.4)                | <.001      |       |        |
| Parent with asthma                   | 31 (25–37)        | 36 (28–44)   | 29 (24–35)      | 1.2 (1.01–1.5)               | .037       |       |        |

Table 3. History of Atopy and Allergic Comorbidities by Atopic Dermatitis Status*

AD, atopic dermatitis; CI, confidential interval; PR, prevalence ratio.

*Percent are marginal predictions and prevalence ratio is the exponentiated coefficient from a log-binomial (relative risk) model for
the comorbidity including AD and age (months) as predictors. P values are from the Wald test for AD vs no AD.
illnesses found a higher prevalence rate in the primary care setting than in the population setting.\textsuperscript{10,11} Measuring the prevalence of AD in children attending primary care clinics reflects the disease burden in these community clinics, whereas population-based studies provide estimates for a general population that may or may not be accessing the health care system.\textsuperscript{10} Understanding the disease burden is important from both perspectives to provide information to investigators, clinicians, patients, and resource allocation stakeholders.

Table 4. Skin Care Practices by Atopic Dermatitis Status\textsuperscript{*}

| Skin Care Practice                  | Overall | AD      | No AD   | P value |
|------------------------------------|---------|---------|---------|---------|
|                                    | % (95% CI) | % (95% CI) | % (95% CI) |         |
| N                                  | 652 (71–84) | 159 (84–96) | 493 (66–82) | <.001   |
| Any current moisturizer use (%)    | 78 (71–84) | 90 (84–96) | 74 (66–82) | <.001   |
| Among current moisturizer users (N)| 500 (66–82) | 144 (78–96) | 356 (42–97) |         |

Where moisturizer applied

- All over body: 91 (88–94) vs 88 (81–94) vs 93 (90–95)
- Just to dry, flaky, or red spots: 9 (6–12) vs 13 (6–19) vs 7 (5–10)

Type of moisturizer(s) used\textsuperscript{†}

| Type of moisturizer(s) used†   | Overall | AD      | No AD   | P value |
|--------------------------------|---------|---------|---------|---------|
|                                  | % (95% CI) | % (95% CI) | % (95% CI) |         |
| Lotion                          | 54 (47–61) | 29 (18–40) | 64 (58–70) | <.001   |
| Ointment                        | 28 (20–35) | 41 (33–49) | 22 (13–31) | <.001   |
| Cream                           | 14 (8–19) | 24 (17–32) | 9 (4–14)  | <.001   |
| Liquid Oil                      | 4 (3–6)  | 7 (3–11)  | 3 (2–5)   | .05     |
| Unspecified lotion or cream     | 32 (28–36) | 38 (29–47) | 29 (25–33) | .022    |

AD, atopic dermatitis; CI, confidential interval.

\textsuperscript{*Percents are mean predictions from a logistic model with age (months) and clustered standard errors to account for correlation between babies from the same clinic. P values are from Wald test for AD vs no AD adjusted for age.

\textsuperscript{†Multiple answers possible to type of moisturizer.

Table 5. Proportions of patients reporting frequent (>4 days per week) bathing and moisturizer by age and Atopic Dermatitis Status\textsuperscript{*}

| Child age | Overall | AD      | No AD   |
|-----------|---------|---------|---------|
|           | N % (95% CI) | N % (95% CI) | N % (95% CI) |
| FREQUENT BATHING (≥4 days per week) |          |         |         |
| <1        | 224 (56–53) | 33 (53–58) | 191 (49–53) |
| 1         | 158 (63–78) | 38 (52–74) | 120 (64–81) |
| 2 to 3    | 124 (57–82) | 37 (43–92) | 87 (58–82) |
| 4 to 5‡   | 111 (51–76) | 44 (41–82) | 67 (47–81) |
| Total     | 617 (52–67) | 152 (47–69) | 465 (52–68) |
| FREQUENT MOISTURIZER USE\textsuperscript{†} (≥4 days per week) |          |         |         |
| <1        | 173 (53–67) | 30 (67–87) | 143 (50–64) |
| 1         | 132 (62–67) | 35 (67–82) | 97 (59–81) |
| 2 to 3    | 95 (57–82)  | 33 (70–88) | 62 (45–84) |
| 4 to 5§   | 77 (47–75)  | 41 (60–82) | 36 (31–69) |
| Total     | 477 (57–73) | 139 (69–81) | 338 (52–70) |

AD, atopic dermatitis; CI, confidential interval.

\textsuperscript{*Percents are mean predictions from a logistic model with clustered standard errors to account for correlation between babies from the same clinic.

\textsuperscript{†Total N (denominator) for given age/AD group.

\textsuperscript{§The denominator for moisturizers frequency includes only those who reported using moisturizers on their child skin.

\textsuperscript{§Includes children aged 6 years, 0 months.

doi: 10.3122/jabfm.2019.02.180225  Childhood Atopic Dermatitis in Primary Care  197
Similar to population-based studies, our study confirmed that allergic comorbidities are also common in children with AD attending community-based primary care clinics. The consistency of our data with other national surveys of allergic diseases lends support that our sample population adequately represents the US AD population. For example, the overall prevalence of asthma found in our sample population of 0 to 5 year olds of 7% closely mirrors the Centers for Disease Control and Prevention statistics from the Behavioral Risk factor Surveillance System 2013 data, which measured the lifetime prevalence of asthma in the general US population to be 7.3% among children under the age of 5. We also confirmed the higher rate of asthma among those with AD (16%) compared to non-AD children (4%) consistent with many previous studies. Patients with AD also had a higher prevalence of a family history of allergic disease in our study, confirming that a family history of atopy represents an important risk factor for AD development.

This study provides insight into skin care practices used in the very young—a subject of relatively limited study, especially given our new understanding of the importance of the skin barrier in the development of AD. Kelleher and colleagues found skin barrier function in the first 2 months of life to be the strongest predictors of AD development. Thus, skin care practices that have the potential to alter skin barrier function may represent important determinants or modifiers of AD development. In this study, the majority of caregivers applied some kind of moisturizer on their child’s skin, even among children without reported AD diagnosed by a health care provider. As expected, children with AD reported more frequent use of thick moisturizers (ie, creams and ointments) than those without AD, as this is the most common first-line treatment for mild AD. Thus, children with AD seem to receive appropriate education regarding moisturizer use supported by published treatment guidelines. In those without AD, we found the majority of parents used more water-based moisturizers (ie, lotions) on the skin, as opposed to thicker moisturizers, with the majority of usage more than 4 days per week. These skin care practices are similar to those described in a single-center study in Oregon and confirm findings from a market-based study showing a very high use of water-based moisturizers (lotions) in babies on a regular basis. This high use of moisturizers is likely a result of cultural preferences or marketing, as skin care guidelines for neonates do not recommend a routine use of moisturizers. The US Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN) released updated guidelines for neonate and infant skin care that state it is unclear whether the routine use of moisturizers benefits infant health. Certain moisturizers could potentially even harm the skin barrier with frequent use, such as those with irritants, fragrances, or high water content, thus potentially provoking AD in genetically susceptible neonates. There is no clinical evidence, however, that the use of fragranced lotions in neonates promotes AD. The guidelines do recommend moisturizer use for dry or cracking skin and routine use for AD and infantile seborrheic dermatitis. Published guidelines from a European roundtable meeting on best practice for infants recommend routine moisturizer/moisturized cleanser use during and after bathing for infants who are at high risk of developing AD if it is needed based on their skin condition. It is unclear what influence the frequency and type of moisturizer used has on the development of AD. Further studies are needed to inform best practices in the general population.

Similar to moisturizer use, the type and frequency of bathing is an understudied area in newborn health. Several studies found that exposure to water alone can be detrimental to the skin barrier, although no studies have evaluated the clinical effects of various methods of bathing or frequency on AD development. We found that more than half of the participants received baths/showers on 4 or more days per week. These results are in agreement with a previous case-control study that found the mean frequency of baths children received was 4 to 5 per week. The current AWHONN guidelines for neonates and infants recommended bathing infants every few days and no more than every other day. In addition, AWHONN concluded that there were no clear benefits from daily bathing; however, they left the decision about frequency of bathing to be based on individual neonate’s needs considering the family beliefs and culture. Similar recommendations were published in 2009 by the European roundtable meeting on best practice for infants that recommend bathing 2 to 3 times a week by using a mild cleanser and concluded that bathing does not harm the baby.

The strengths of our study include the use of primary care-based sampling to better understand...
AD burden in the primary care clinical setting, the use of clinics that are members of PBRNs experienced in executing research protocols, and the inclusion of questions regarding skin care practices that are usually overlooked in AD surveys. Limitations of the study are that we cannot exclude the potential for selection bias that could yield artificially inflated prevalence rates. Because of regional variation in AD prevalence, the prevalence data from the states included in this study may not be generalizable to all states in the United States. In addition, the diagnosis of AD was made by parental report of a health care provider diagnosis rather than direct examination by a provider. Last, a possible failure to complete the survey existed for children with more complex health care visits, such as those with chronic health conditions.

In conclusion, our study found a large burden of AD in the primary care practice setting in the United States. The majority of households use skin care practices that may be detrimental to the skin barrier of children not diagnosed with AD, such as frequent bathing and the use of watery lotions frequently. Clinical trials will allow us to identify which skin care practices are optimal for reducing the significant burden of AD in the community.

The authors thank the families who donated their time to participate, the participating clinicians, and the following research assistants who helped collect and manage data—Chou Xiong, Erica Suarez, Danielle Smith, and Annette Vu.

To see this article online, please go to: http://jabfm.org/content/32/2/191.full.

References
1. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005;352:2314–24.
2. Hanifin JM, Reed ML. A population-based survey of eczema prevalence in the United States. Dermatitis 2007;18:82–91.
3. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016;387:1109–22.
4. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2014;134:1527–34.
5. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009;124:1251–8.e1223.
6. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351:1225–32.
7. Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLoS One 2012;7:e39803.
8. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Invest Dermatol 2011;131:67–73.
9. Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis 2014;25:107–14.
10. Mokraoui NM, Haggerty J, Almirall J, Fortin M. Prevalence of self-reported multimorbidity in the general population and in primary care practices: a cross-sectional study. BMC Res Notes 9:314, 2016.
11. Fortin M, Hudon C, Haggerty J, van den Akker M, Almirall J. Prevalence estimates of multimorbidity: a comparative study of two sources. BMC Health Serv Res 2010;10:111.
12. Silverberg JI, Hanifin J, Simpson EL. Climatic factors are associated with childhood eczema prevalence in the United States. J Invest Dermatol 2013;133:1752–9.
13. Bisgaard H, Simpson A, Palmer CN, et al. Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLoS Med 2008; 5:e131.
14. Lu C, Deng L, Ou C, Yuan H, Chen X, Deng Q. Preconceptional and perinatal exposure to traffic-related air pollution and eczema in preschool children. J Dermatol Sci 2017;85:85–95.
15. Kelleher M, Dunn-Galvin A, Hourihane JO, et al. Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year. J Allergy Clin Immunol 2015;135:930–5.e931.
16. New neonatal skin care evidence-based practice guideline. Nursing for Women’s Health. 2013;17:545–6.
17. Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis at 1 year. J Allergy Clin Immunol 2015;135:930–5.e931.
18. Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014;134:824–30.e826.
19. Lowe AJ, Su JC, Allen KJ, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol 2018;178:e19–e21.

doi: 10.3122/jabfm.2019.02.180225
20. Caussin J, Groenink HW, de Graaff AM, et al. Lipophilic and hydrophilic moisturizers show different actions on human skin as revealed by cryo scanning electron microscopy. Exp Dermatol 2007;16:891–8.

21. Cork MJ, Robinson D, Vasilopoulos Y, et al. Pre-disposition to sensitive skin and atopic eczema. Community Pract 2005;78:440–2.

22. Westfall JM, Mold J, Fagnan L. Practice-based research—“Blue Highways” on the NIH roadmap. JAMA 2007;297:403–6.

23. von Kobyletzki LB, Berner A, Carlstedt F, Hasselgren M, Bornegah CG, Svensson A. Validation of a parental questionnaire to identify atopic dermatitis in a population-based sample of children up to 2 years of age. Dermatology 2013;226:222–6.

24. Silverberg JI, Patel N, Immaneni S, et al. Assessment of atopic dermatitis using self-report and caregiver report: a multicentre validation study. Br J Dermatol 2015;173:1400–4.

25. Garg NK, Silverberg JI. Eczema is associated with osteoporosis and fractures in adults: a US population-based study. J Allergy Clin Immunol 2015;135:1085–7.e1082.

26. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000;43:649–55.

27. Pustisek N, Vurnek Zivkovic M, Situm M. Quality of life in families with children with atopic dermatitis. Pediatr Dermatol 2016;33:28–32.

28. Draaisma E, Garcia-Marcos L, Mallol J, Sole D, Perez-Fernandez V, Brand PL. A multinational study to compare prevalence of atopic dermatitis in the first year of life. Pediatr Allergy Immunol 2015;26:359–66.

29. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol 1996;34:760–764.

30. Centers for Disease Control and Prevention. Data, statistics, and surveillance. Asthma surveillance data. Available from: http://www.cdc.gov/asthma/asthmadata.htm. Published 2016.

31. Ziyab AH, Karmanus W, Zhang H, et al. Association of filaggrin variants with asthma and rhinitis: is eczema or allergic sensitization status an effect modifier? Int Arch Allergy Immunol 2014;164:308–18.